Yes

Antispasmodic Agent, Urinary

Antispasmodic for neurogenic bladder (urgency, frequency, urge incontinence) and uninhibited bladder

B

Glaucoma, myasthenia gravis, partial or complete GI obstruction, GU obstruction, ulcerative colitis, hypersensitivity to drug or specific component, intestinal atony, megacolon, toxic megacolon

Use with caution in patients with urinary tract obstruction, angle-closure glaucoma, hyperthyroidism, reflux esophagitis, heart disease, hepatic or renal disease, prostatic hypertrophy, autonomic neuropathy, ulcerative colitis (may cause ileus and toxic megacolon), hypertension, hiatal hernia. Caution should be used in elderly due to anticholinergic activity (eg, confusion, constipation, blurred vision, and tachycardia).

>10%:

Central nervous system: Drowsiness

Gastrointestinal: Xerostomia, constipation

Miscellaneous: Diaphoresis (decreased)

1% to 10%:

Cardiovascular: Tachycardia, palpitations

Central nervous system: Dizziness, insomnia, fever, headache

Dermatologic: Rash

Endocrine & metabolic: Decreased flow of breast milk, decreased sexual ability, hot flashes

Gastrointestinal: Nausea, vomiting

Genitourinary: Urinary hesitancy or retention

Neuromuscular & skeletal: Weakness

Ocular: Blurred vision, mydriatic effect

<1%: Increased intraocular pressure, allergic reaction

Symptoms of overdose include hypotension, circulatory failure, psychotic behavior, flushing, respiratory failure, paralysis, tremor, irritability, seizures, delirium, hallucinations, coma

Symptomatic and supportive treatment; induce emesis or perform gastric lavage followed by charcoal and a cathartic; physostigmine may be required; treat hyperpyrexia with cooling techniques (ice bags, cold applications, alcohol sponges)

Increased toxicity:

Additive anticholinergic effects with antihistamines and anticholinergic agents

Direct antispasmodic effect on smooth muscle, also inhibits the action of acetylcholine on smooth muscle (exhibits 1/5 the anticholinergic activity of atropine, but is 4-10 times the antispasmodic activity); does not block effects at skeletal muscle or at autonomic ganglia; increases bladder capacity, decreases uninhibited contractions, and delays desire to void; therefore, decreases urgency and frequency

Onset of effect: Oral: 30-60 minutes

Peak effect: 3-6 hours

Duration: 6-10 hours

Absorption: Oral: Rapid and well absorbed

Metabolism: In the liver

Half-life: 1-2.3 hours

Time to peak serum concentration: Within 60 minutes

Elimination: In urine

Oral:

1-5 years: 0.2 mg/kg/dose 2-4 times/day

>5 years: 5 mg twice daily, up to 5 mg 4 times/day maximum

Adults: 5 mg 2-3 times/day up to 5 mg 4 times/day maximum

Extended release: Initial: 5 mg once daily, may increase in 5-10 mg increments; maximum: 30 mg daily

Elderly: 2.5-5 mg twice daily; increase by 2.5 mg increments every 1-2 days

Note: Should be discontinued periodically to determine whether the patient can manage without the drug and to minimize resistance to the drug

Should be administered on an empty stomach with water

Incontinence episodes, postvoid residual (PVR)

May suppress the wheal and flare reactions to skin test antigens

Drowsiness is common; may cause insomnia or dizziness

Concurrent use with psychotropics may produce additive sedation and anticholinergic side effects (dry mouth)

No information available to require special precautions

>10% of patients experience dry mouth; prolonged use of oxybutynin may decrease or inhibit salivary flow; normal salivation returns with cessation of drug therapy

Take prescribed dose preferably on an empty stomach (1 hour before or 2 hours after meals). You may experience dizziness, lightheadedness, or drowsiness (use caution when driving or engaging in tasks requiring alertness until response to drug is known); dry mouth or changes in appetite (small frequent meals, frequent mouth care, sucking lozenges, or chewing gum may help); constipation (frequent exercise or increased dietary fiber, fruit, and fluid or stool softener may help); decreased sexual ability (reversible with discontinuance of drug); decreased sweating (use caution in hot weather, avoid extreme exercise or activity). Report rapid heartbeat, palpitations, or chest pain; difficulty voiding; or vision changes. Swallow extended-release tablets whole, do not chew or crush. Breast-feeding precautions: Do not breast-feed.

Raise bed rails, institute safety measures, assist with ambulation

Syrup, as chloride: 5 mg/5 mL (473 mL)

Tablet, as chloride: 5 mg

Tablet, as chloride, extended release: 5 mg, 10 mg, 15 mg